Application of sacubitril/valsartan in patients with chronic kidney disease
10.3760/cma.j.cn441217-20230330-00343
- VernacularTitle:沙库巴曲缬沙坦在慢性肾脏病患者中的应用
- Author:
Yi HE
1
;
Hui ZHONG
;
Hen XUE
;
Youqin YANG
;
Min ZHAO
;
Xiaodong CHANG
;
Maoli CHEN
;
Ping FU
Author Information
1. 雅安市人民医院肾脏内科 四川大学华西医院雅安医院，雅安 625000
- Keywords:
Valsartan;
Renal insufficiency, chronic;
Heart failure;
Hypertension;
Chronic kidney disease;
Sacubitril
- From:
Chinese Journal of Nephrology
2024;40(1):67-73
- CountryChina
- Language:Chinese
-
Abstract:
As a new strategy for the application of sacubitril/valsartan (LCZ696) in patients with CKD, much evidence showed that it improved the prognosis of patients with CKD. This review summarizes the efficacy and safety of sacubitril/valsartan in physiology, pathology, pharmacology and clinical application by searching Wanfang, CNKI, PubMed and other databases for related articles on the application of sacubitril/valsartan in CKD patients. Although LBQ657, the active product of sacubitril, has a high drug accumulation in patients with moderate, severe renal injury, and ESRD, it is not cleared in hemodialysis, and has very little eliminated in peritoneal dialysis, which does not affect its safety. Compared with angiotensin converting enzyme inhibitor and angiotensin receptor blocker drugs, LCZ696 could increase the blood pressure control rate, improve cardiac function, slow down the decline of glomerular filtration rate, and significantly improve cardiovascular outcomes without more adverse events. Sacubitril/valsartan can be used in all levels of CKD patients complicated with hypertension and/or heart failure, with reliable safety and tolerance.
